Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Other

ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function

About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with...
solaci -
Learn More
Other

ESC 2022 | SECURE Trial

This study, presented by Dr. Valentin Fuster, focused on the importance of medical treatment compliance, initially showing...
solaci -
Learn More
Other

ESC 2022 | TIME STUDY

The TIME study, presented by Dr. Thomas MacDonald, is a randomized study of over 21,000 patients with...
solaci -
Learn More
Antiplatelet

Ticagrelor Monotherapy: Valid after 12 Months?

Recent studies on antiplatelet antiaggregation support the use of short dual antiaggregation therapy (DAPT), even in unforeseen...
solaci -
Learn More
Day 2

SOLACI-SOCIME 2022 | El Desafío de PCI en pacientes con HBR, by Dr. Aníbal Damonte

Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult...
solaci -
Learn More
Antithrombotic Anticoagulants

Are Elevated Lipoprotein (a) Levels Associated with Increased Adverse Events After Peripheral Endovascular Treatment?

Peripheral arterial disease is a manifestation of systemic atherosclerotic disease with increasing prevalence. Moreover, this disease is...
solaci -
Learn More
Antithrombotic Anticoagulants

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in...
solaci -
Learn More
Antiplatelet

An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy